Patents by Inventor Takuma YOSHIMURA

Takuma YOSHIMURA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250186469
    Abstract: What is provided is a therapeutic agent that is effective for the treatment of ovarian clear cell carcinoma. A therapeutic agent for ovarian clear cell carcinoma includes, as an active ingredient, a proteasome inhibitor. Furthermore, in the therapeutic agent for ovarian clear cell carcinoma, the proteasome inhibitor is a substance that reversibly or irreversibly binds to a 20s proteasome-?5 subunit and inhibits a chymotrypsin-like activity. Moreover, in the therapeutic agent for ovarian clear cell carcinoma, the proteasome is a 26s proteasome. In addition, in the therapeutic agent for ovarian clear cell carcinoma, a content proportion of the proteasome inhibitor is 80% by mass or more, 90% by mass or more, or 100% by mass.
    Type: Application
    Filed: January 30, 2025
    Publication date: June 12, 2025
    Applicants: JSR CORPORATION, KEIO UNIVERSITY
    Inventors: Aki OOKUBO, Tatsuyuki CHIYODA, Takuma YOSHIMURA
  • Publication number: 20230058473
    Abstract: A spherical core containing an esomeprazole compound as an active ingredient and having a median particle diameter (d50) of 50 ?m or more is coated with a coat containing a controlled release layer to prepare a controlled release granule containing a controlled release granule with a median particle diameter (d50) of 350 ?m or less. The spherical core may contain the esomeprazole compound at a proportion of 50% by mass or more relative to the spherical core. The spherical core may be a spherical particle containing the esomeprazole compound as a drug. The spherical core has a median particle diameter (d50) of 50 ?m or more. The spherical core may have a sphericity of 0.6 or more. The coat may be in a multilayer free from an esomeprazole compound as an active ingredient. The controlled release layer may be an enteric coating layer. The proportion of the coat may be 80% by mass or more relative to the whole amount of the preparation.
    Type: Application
    Filed: January 26, 2021
    Publication date: February 23, 2023
    Applicant: TOWA PHARMACEUTICAL CO., LTD.
    Inventors: Keisuke HIRAISHI, Takuma YOSHIMURA, Tatsuya HONJO, Isamu SAEKI, Yutaka OKUDA